Roche and GSK ink new deal, settle old score

Roche and GlaxoSmithKline have inked a licensing deal for the obesity drug Orlistat while agreeing to drop litigation over a separate licensing deal. Roche provided an unspecified settlement to GSK. GSK gained the exclusive non-prescription rights to Orlistat outside of the U.S. and Japan. And all claims regarding the marketing of Carvedilol were dropped.

- here's the MarketWatch report on the settlement

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.